Pharma Development Support

Accelerating Research & Drug Development

We empower pharmaceutical companies, researchers, CROs, and academic teams with powerful tools and expert guidance to drive faster, smarter drug development.
We offer two paths to insight:

SAAS PLATFORM

“Discover Mavatar’s SaaS Platform”

A self-service, cloud-based research platform for advanced, 100% data-driven analysis of public and biomedical data.

 Ideal for identifying biomarkers, exploring disease mechanisms, and generating ready-to-use insights—no bioinformatics team required.


PLATFORM

Mavatar|Discovery

Taking Research to the Next Level

Go To Page
TAILORED SERVICE

Mavatar Collab

Your Scientific Partner in Clinical Trials & Precision Medicine.
Mavatar Collab offers tailored support for pharma teams—combining our cutting-edge AI technology with hands-on guidance from our world-class team of experts.
Whether you're identifying new targets, refining mechanisms of action, or optimizing trial design, we deliver curated insights to accelerate your research.
Work with us to turn complex data into real-world breakthroughs.

Get in touch

What do we offer?

Bringing your research to the Future

Read about what Mavatar brings to the table with our Pharma Development Support

PHARMA DEVLEOPMENT SUPPORT

End to End Solution

  • Turnkey solution that works out of the box—no complex setup required.

PHARMA DEVLEOPMENT SUPPORT

Integrated Analysis

  • Deep integrated network analysis on all disease mechanisms, such as genes, cells, and signaling pathways.

PHARMA DEVLEOPMENT SUPPORT

AI and Data-Driven Pipeline

  • Unique ability to unify, analyze, and translate large amounts of medical data and deliver new insights in a data driven format.

COLLABORATIONS

Pharma Collaborations

Mavatar has active collaboration with several big pharma.
Some example of collabs are:

collab

Ulcerative Colitis

collab

Ulcerative Colitis

Newly released product, approved for 5th line treatment.

The client seeks approval for the product as 1st line treatment - our aim is to discover newly diagnosed patients that may be suited recipients for the new product.

SOW is under negotiation

collab

Multiple Myeloma

collab

Multiple Myeloma

Newly released product, which is effective in ~35% of patients

The client seeks biomarkers that identify suitable recipients of the new product

Project is ongoing, with completed feasibility study

collab

Alzheimer's Galectin III

collab

Alzheimer's Galectin III

Galectin III effect on brain diseases with special focus on Alzheimer.